Practical Management of Boceprevir and Immunosuppressive Therapy in Liver Transplant Recipients with Hepatitis C Virus Recurrence

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2012-08-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.01151-12PMID 22908172PMCID PMC3486528
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

  2013cited by this paper
• Preliminary study of two antiviral agents for hepatitis C genotype 1.

  2012cited by this paper
• Cyclosporine A- and Tacrolimus-Mediated Inhibition of CYP3A4 and CYP3A5 In Vitro

  2012cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• Boceprevir for previously treated chronic HCV genotype 1 infection.

  2011cited by this paper
• Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

  2011cited by this paper
• Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents — A potentially lethal cocktail

  2011cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• Characterization of Human Liver Enzymes Involved in the Biotransformation of Boceprevir, a Hepatitis C Virus Protease Inhibitor

  2011cited by this paper
• Boceprevir

  2011cited by this paper
• Drug Interactions Should Be Evaluated in Patients

  2010cited by this paper
• Management of Drug and Food Interactions with Azole Antifungal Agents in Transplant Recipients

  2010cited by this paper
• Drug interactions in transplant patients: what everyone should know

  2009influential reference
• Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients.

  2009cited by this paper
• Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis

  2008cited by this paper
• Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring.

  2008cited by this paper
• Early histologic changes in fibrosing cholestatic hepatitis C

  2007cited by this paper
• Effect of Highly Active Antiretroviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus and HIV Co-Infected Liver Transplant Recipients in the ANRS HC-08 Study

  2007cited by this paper
• Factors Influencing the Magnitude and Clinical Significance of Drug Interactions Between Azole Antifungals and Select Immunosuppressants

  2006cited by this paper
• Population Pharmacokinetic Estimation of Tacrolimus Apparent Clearance in Adult Liver Transplant Recipients

  2005cited by this paper
• Long‐term results and modeling to predict outcomes in recipients with HCV infection: Results of the NIDDK liver transplantation database

  2004cited by this paper
• Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications

  2001cited by this paper
• Natural history of clinically compensated hepatitis C virus–related graft cirrhosis after liver transplantation

  2000influential reference
• An algorithm for the grading of activity in chronic hepatitis C

  1996cited by this paper
• Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals.

  1995cited by this paper

• In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor

  2021cites this paper
• Drug Metabolism, Drug Interactions, and Drug-Induced Liver Injury in Living Donor Liver Transplant Patients.

  2017cites this paper
• Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.

  2016cites this paper
• Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection

  2016cites this paper
• EASL Clinical Practice Guidelines: Liver transplantation.

  2016cites this paper
• Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir‐based therapy

  2016cites this paper
• Interferon‐free antiviral treatment of chronic hepatitis C in the transplant setting

  2015cites this paper
• Indications for Liver Transplantation

  2015cites this paper
• Management of post transplant hepatitis C in the direct antiviral agents era

  2015influential citation
• Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals

  2015cites this paper
• Advances in therapy for HIV/hepatitis C virus-coinfected patients in the liver transplant setting.

  2015cites this paper
• Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?

  2015cites this paper
• Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review

  2015cites this paper
• Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation

  2015cites this paper
• Chapter 11 – Transplantation for Hepatitis C

  2015cites this paper
• Boceprevir in liver transplant recipients

  2015cites this paper
• Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?

  2015cites this paper
• Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.

  2014influential citation
• Interferon-Free Regimens in the Liver-Transplant Setting

  2014cites this paper
• Risk factors and management of hepatitis C recurrence after liver transplantation

  2014cites this paper
• Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?

  2014cites this paper
• Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances

  2014cites this paper
• [Drug-drug interaction with telaprevir or boceprevir in liver transplant patients: about four cases].

  2014cites this paper
• Recurrent HCV after liver transplantation—mechanisms, assessment and therapy

  2014cites this paper
• CXCL10 levels identify individuals with rapid fibrosis at 12 months post‐transplant for hepatitis C virus and predict treatment response

  2014cites this paper
• Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease.

  2014cites this paper
• Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.

  2014influential citation
• Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation.

  2014influential citation
• Reply to: "Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation".

  2014cites this paper
• Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents?

  2014cites this paper
• Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation.

  2014cites this paper
• Hepatitis C virus recurrence after liver transplantation: how to treat and when.

  2014cites this paper
• Triple antiviral therapy with telaprevir after liver transplantation: a case series

  2014influential citation
• Hepatitis C and Liver Transplantation in the HIV Co-infected Patients

  2014cites this paper
• Optimal Management of HCV Transplant Patients

  2014cites this paper
• Interactions avec télaprévir ou bocéprévir chez des patients greffés hépatiques : à propos de 4 cas cliniques

  2014cites this paper
• Management of viral hepatitis in liver transplant recipients

  2014cites this paper
• Victory and defeat at Heraclea - treating hepatitis C infection following liver transplantation with telaprevir and boceprevir.

  2014cites this paper
• Management of HCV transplant patients with triple therapy

  2014cites this paper
• Current management and perspectives for HCV recurrence after liver transplantation

  2013cites this paper
• Update on donor‐derived infections in liver transplantation

  2013cites this paper
• Current World Literature

  2013cites this paper
• Who is taking up voluntary medical male circumcision? Early evidence from Tanzania

  2013cites this paper
• Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors

  2013cites this paper
• [Pharmacokinetic interactions of telaprevir with other drugs].

  2013cites this paper
• Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft

  2013cites this paper
• Management of recurrent hepatitis C in orthotopic liver transplant recipients.

  2013cites this paper
• The importance of drug-drug interactions in the DAA era.

  2013cites this paper
• Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients

  2013influential citation
• Treatment of chronic hepatitis C virus infection after liver transplantation.

  2013cites this paper
• The new era of hepatitis C treatment: still the tip of the iceberg?

  2013cites this paper
• Frontiers in Liver Transplantation Drug-drug interactions with oral anti-HCV agents and Idiosyncratic Hepato- toxicity in the Liver Transplant setting

  2013influential citation
• Direct Antiviral Agents for the Treatment of Hcv Reinfection after Liver

  2013influential citation
• The Management of HCV Recurrence after Liver Transplantation

  2013cites this paper